Myriad Genetics (MYGN) Goodwill (2011 - 2026)

Myriad Genetics (MYGN) has reported Goodwill for 16 consecutive years, with $47.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Goodwill fell 83.55% year-over-year to $47.1 million; the TTM figure through Mar 2026 stood at $47.1 million (down 83.55% YoY), while the FY2025 annual figure was $51.6 million, down 81.98% from the prior year.
• Goodwill retreated to $47.1 million in Q1 2026 per MYGN's latest filing, from $51.6 million in the prior quarter.
• Across five years, Goodwill topped out at $287.4 million in Q4 2023 and bottomed at $47.1 million in Q1 2026.
• Historically, Goodwill has averaged $222.5 million across 5 years, with a median of $286.3 million in 2024.
• Annual changes were most pronounced in 2023 — Goodwill climbed 21.18% — and 2026, when it plunged 83.55%.
• Myriad Genetics' Goodwill stood at $286.8 million in 2022, then increased by 0.21% to $287.4 million in 2023, then declined by 0.38% to $286.3 million in 2024, then sank by 81.98% to $51.6 million in 2025, then dropped by 8.72% to $47.1 million in 2026.
• Business Quant data shows MYGN's Goodwill at $47.1 million in Q1 2026, $51.6 million in Q4 2025, and $51.6 million in Q3 2025.